NLRP3 and tuberculosis: Findings in the present work may support the use of statins as adjuvant drugs in treating tuberculosis but, they also alert on the potential of these drugs to exacerbate pre-existing inflammatory diseases linked to a sterile activation of the NLRP3 inflammasome [92], for example, as observed in diabetes mellitus type I [93].